Following a September 2024 pipeline prioritization and approximately 49% workforce reduction, the company is focusing on generating robust clinical data from INB-100, its lead candidate. INB-100 targets acute myeloid leukemia with haplo-matched allogeneic gamma-delta T cells post-hematopoietic stem cell transplant, while INB-200/400 programs evaluate autologous DeltEx DRI gamma-delta T cells for glioblastoma, with INB-600 advancing novel gamma-delta T cell engagers.
Cyborg Score Rationale
Early data show long-term complete remissions in acute myeloid leukemia after haploidentical transplants and roughly doubled median progression-free survival in glioblastoma patients, supporting continued clinical development. However, management notes substantial doubt about continuing as a going concern, indicating that additional financing or partnerships are critical.
Top Insights
INB-100 Phase 1 trial showed all evaluable patients in durable complete remission with six patients remaining relapse-free beyond one year and in vivo expansion/persistence of allogeneic gamma-delta T cells out to 365 days.
Company achieved 100% one-year progression-free survival observed to date in acute myeloid leukemia patient population.
Updated Phase 1 and 2 data from INB-200/400 program in newly diagnosed glioblastoma to be presented at SNO Annual Meeting (November 2025) and preclinical data from INB-619 gamma-delta T cell engager program at ASH Annual Meeting (December 2025).
Strategic pause on clinical trial-related activities for INB-400 program implemented during 2024 pipeline prioritization.
Named Competitors
CAR-T Cell Therapy — Established chimeric antigen receptor T cell immunotherapies
Checkpoint Inhibitors — PD-1/PD-L1 inhibitors for hematologic and solid tumors
NK Cell Therapies — Natural killer cell-based immunotherapy approaches
Recent Developments
(September 2024) Announced pipeline prioritization and ~49% workforce reduction to focus resources on INB-100 for acute myeloid leukemia
(Q3 2025) Reported R&D expenses of $2.1 million with strategic pause on INB-400 clinical activities
(April 2026) Reported fourth quarter and full-year 2025 financial results highlighting durable survival improvements in glioblastoma and strengthened financial position for 2026
Open the full interactive IN8bio, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.